Huahai force 1 billion schizophrenic drugs! Just won the first review of the new dosage form is coming soon
-
Last Update: 2020-07-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Pharmaceutical Network July 10, CDE official website data show that Huahai Pharmaceuticals' Ali-Yuankou collapse 3 class of generic listing applications were acceptedMinnet data show that Huahai Pharmaceuticals' application for a generic listing of 4 types of alysium tablets was approved in March 2020, becoming the first enterprise to evaluate the product, this declaration of the collapse of the tablet, it can be seen that Huahai has sufficient confidence in the variety of ali-YuanFigure 1: Huahai Pharmaceuticals' Ali-Yuankou collapse report informationSource: CDE official website
Figure 2: Sales of Alysium (units: 10,000 yuan)Source: Mine net China's public medical institutions terminal competition pattern
alyfense mainly used for the treatment of schizophrenia In 2019, China's urban publichospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal psychostable drug generic name TOP20 ranked fifth, sales rose to 1.15 billion yuan, according to Minet.comFrom the dosage form, the largest proportion of general tablets, more than 63%, the leadingenterprisesfor Otsuka Pharmaceuticals;Table 1: Huahai Pharmaceuticals' alysium-related productdeclarationSource: MED China Drug Review Database 2.0Huahai Pharmaceuticals is a representative pharmaceutical company of API-preparation integration, Minet data show that earlier Huahai Pharmaceuticals already has a listeric fennel api, ordinary tablets were also approved in March 2020 and treated as the same, after the successful approval of the oral tablets, will greatly enhance the competitiveness in the market Source: CDE official website, Minnet database
review data as of July 9, 2020, if there are any errors, please indicate
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.